A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab.
J Endocrinol Invest
; 41(7): 877-878, 2018 07.
Article
in En
| MEDLINE
| ID: mdl-29804271
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adenocarcinoma
/
Antineoplastic Combined Chemotherapy Protocols
/
Graves Ophthalmopathy
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
J Endocrinol Invest
Year:
2018
Document type:
Article